Skip to content

Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06012968
Enrollment
10
Registered
2023-08-28
Start date
2023-08-31
Completion date
2023-10-31
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Surgical Procedures

Brief summary

This study intends to include hypertrophic cardiomyopathy patients over 18 years old who underwent cardiac surgery in our hospital. Patients were divided into medication group and control group according to the use of gastrodin during operation. The patients ' myocardial tissue samples were collected, the postoperative prognosis data were observed and recorded, and the data were analyzed. The degree of myocardial tissue cell damage and postoperative clinical outcomes were compared between the two groups.

Interventions

None listed

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with hypertrophic cardiomyopathy aged≥18 years, regardless of gender; * Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery; * Signed informed consent, good compliance.

Exclusion criteria

* suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.); * moderate to severe malnutrition, moderate to severe anemia; * persistent infection; * severe preoperative underlying diseases (such as severe liver and kidney dysfunction)

Design outcomes

Primary

MeasureTime frameDescription
Degree of myocardial cell injuryDuring postoperative hospitalization stay, an average of about two weeksPostoperative myocardial injury marker serum concentration, postoperative cardiac function ultrasound index

Countries

China

Contacts

Primary ContactQingping Wu, doctor
wqp1968@126.com13971605283

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026